Ticagrelor for preventing atherothrombotic events after myocardial infarction

comments that ticagrelor would be valued as an option for these people, it should include this group. The committee further concluded that although there may be only a minority of patients in this position, it was not appropriate to exclude these people in decision-making. Decision problem: comparator 4.5 The committee noted that the final scope specified clopidogrel plus aspirin and aspirin alone as comparators and that the company considered aspirin alone to be the appropriate comparator. The committee understood that the company did not consider clopidogrel plus aspirin to be an appropriate comparator because it does not have a marketing authorisation for use more than 12 months after a myocardial infarction and is not considered established clinical practice at that point in the treatment pathway. The committee recognised that although the company did not consider clopidogrel plus aspirin to be an appropriate comparator, it had considered doing an indirect comparison of ticagrelor with clopidogrel plus aspirin because there were no trials directly comparing the 2 treatments. But the company considered this inappropriate (as did the evidence review group; ERG) because of differences in the design of the trials and the patient populations included in the indirect comparison. The committee understood
